Overview
- Under the approved first vote, Indecopi’s five‑member council would include three appointees from the Executive—among them the president—whose designation must be ratified by the Senate, which would also choose the remaining two directors for five‑year terms with immediate reappointment allowed.
- The Senate would have authority to remove council members for grave misconduct by absolute majority, shifting oversight of top appointments away from the Cabinet to a shared Executive‑Legislative model.
- Indecopi’s Competition Commission fined 13 pharmaceutical firms a total of 100,852.72 UIT (over S/539 million) and five executives 262.67 UIT (over S/1.4 million) for collusion in public tenders, in a first‑instance decision open to administrative appeal.
- The case identified coordinated bids and abstentions in at least 23 procurement processes between 2006 and 2020 affecting purchases for MINSA, EsSalud and CENARES, including antibiotics, oncology drugs, immunosuppressants and saline solutions.
- Investigators cited emails, chats, phone records, interviews and judicially authorized access to communications; sanctioned companies must implement competition‑compliance programs for five years while the ruling can be reviewed by Indecopi’s Tribunal and later the courts.